Sareum Holdings welcomed news that Sierra Oncology had reported positive preliminary clinical data from two in-human studies. Sierra Oncology is the licence holder for Chk1 inhibitor SRA737. It reported the data from its two first-in-human Phase 1/2 studies of SRA737 as monotherapy and as SRA737+LDG at the 2019 Annual Meeting of the American Society of Clinical Oncology in Chicago. Anti-cancer activity was demonstrated across multiple indications and genetic contexts, with SRA737+LDG specifically achieving a notable 30% response rate in anogenital cancer patients.
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.